TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04114799

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodynamic management based on invasive fluid responsiveness parameters
Description: In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the SPV value more than 8% will be used as a trigger for the bolus of 2 ml/kg of Plasmalyte (Baxter)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodynamic management based on noninvasive cardiac output and SVV measurement
Description: In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the systemic vascular resistance (SVR) value will be used to trigger norepinephrine infusion. In patients with low SVR norepinephrine infusion will be started. In patients with high SVR value either fluid bolus (in patient with SVV value above 8%), or dobutamine infusion (in patients with SVV value below or equal 8%) will be used.
Study: NCT02302235

Intervention type: OTHER
Group type: OTHER
Intervention: Ketogenic Diet
Description: Treatment will consist of ketogenic diet. KD will consist of 4:1 \[fat\] : \[protein+carbohydrate\] weight ratio with 1600 kcal restriction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Diet
Description: Participants with GBM treated with radiation and temozolomide after surgical debulking treatment. The subjects will be taken standard diet in a 1:1 ratio. Diet will be started at the time of initiation of radiation treatment.
Study: NCT04664530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esketamine
Description: The in-hospital intervention process is divided into a titration phase and an effect evaluation phase. After admission, all patients received pregabalin 150mg twice for one day and amitriptyline 12.5mg one piece per night. The treatment group was combined with intranasal esketamine three times per day, and individualized concentration titration was performed within 5 days. Set the initial dosage to 10mg for nasal drops. If the score is less than 5 points compared to the basic value, the dose is increased by 5 mg each time. When the dose reaches 25mg, the increment of the dose will be adjusted to 10mg. If the score is reduced by ≥5 points compared to the basic value, the current dose will be maintained and the titration will end. The titration phase will be finished when the titration dose reaches 35mg or untolerable adverse reactions occurs. Finally, a 7 tesla scan was performed on the right-hand patients with herpes on the body to explore the effect of ketamine on the brain network.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The titration process in the control group with saline are the same as those in the treatment group with esketamine.
Study: NCT01288612

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sedated Endoscopy
Description: The sedated esophagogastroduodenoscopy procedures were performed using a conventional high-definition endoscope (GIF-180, Olympus America, Center Valley, Pennsylvania) under conscious sedation with intravenous midazolam and fentanyl.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transnasal Endoscopy
Description: Unsedated transnasal endoscopy performed using the EndoSheath transnasal esophagoscope (TNL-5000, Vision Sciences). Topical anesthetic aerosol spray was applied to the posterior pharynx and nasal spray mixture was applied to the patients nares 10-15 minutes before the endoscopy procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transnasal Endoscopy
Description: Unsedated transnasal endoscopy performed using the EndoSheath transnasal esophagoscope (TNL-5000, Vision Sciences). Topical anesthetic aerosol spray was applied to the posterior pharynx and nasal spray mixture was applied to the patients nares 10-15 minutes before the endoscopy procedure.
Study: NCT00030771

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Docetaxel (Taxotere®) 85 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Docetaxel (Taxotere®) 85 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: 3-4 weeks after termination of radiotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: 3-4 weeks after termination of radiotherapy
Study: NCT03790774

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Participants receive intermittent visual and auditory cues to adjust their attentional engagement with a letter identification task.
Study: NCT01766492

Intervention type: RADIATION
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Stereotactic body radiation therapy for prostate
Study: NCT01357824

Intervention type: PROCEDURE
Intervention: Application of Sellick´s maneuver.
Description: The patient will be intubated with a flexible fiberscope, Olympus model, under the application of Sellick´s maneuver, with the recommended 30 Newtons pressure, and also, as control, be intubated with a sham Sellick´s maneuver, with 0 Newton. The order of the pressures is randomized, and it is blinded to the intubating physician by a cloth which of the maneuvers that is used. The pressure is measured be a pediatric cuff, which is pressed against the throat.
Study: NCT02120495

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: condylectomy
Description: The condylectomy via intraoral approach will avoid the risk of facial nerve injury and skin scar compared with the preauricular incision.And it can also greatly reserve the temporomandibular jiont anatomy and function.
Study: NCT01371799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug
Description: Placebo
Study: NCT01344044

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI
Description: 24 half-hour sessions over 8 weeks, i.e. 3 sessions per week, followed by 3 once-monthly boosters.
Study: NCT03978429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based Pre-eclampsia/Eclampsia Detection and Management
Description: Three Community Health Workers (CHWs) per health facility (cluster) will be equipped with android smartphones and blood pressure monitors. The CHWs will visit participant's home once per month until 6 weeks post-partum and complete a Case Report Form for signs and symptoms of pre-eclampsia and blood pressure. CHWs, Antenatal Care Nurses (ANC) at the woman's health facility and study coordinator will receive SMS message if the algorithm on our platform (informed by the Tanzanian Standard Treatment Guidelines (TSTG) deems she is at risk for pre-eclampsia. This message will indicate that the woman needs to be referred to her health facility if: participant has high blood pressure, a significant intrapatient rise in blood pressure or a combination of factors according to an algorithm. Woman's condition will be assessed and ANC will decide on the management, including rest at home with CHW monitoring. Women found to be at risk for pre-eclampsia will be visited twice monthly.
Study: NCT01522612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Every 2 weeks, 400 mg/m2 on day 1; 2400 mg/m2 from day 1 to day 3, intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Every 2 weeks, 400 mg/m2 on day 1; 2400 mg/m2 from day 1 to day 3, intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin
Description: Every 2 weeks, Racemic leucovorin 200 mg/m2 or l-leucovorin 100 mg/m2 on day 1, intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Every 2 weeks, Racemic leucovorin 200 mg/m2 or l-leucovorin 100 mg/m2 on day 1, intravenously
Study: NCT04602949

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Breath Biopsy Analysis
Description: Analysis of a single breath Biopsy
Study: NCT01034488

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Suine
Description: 5000UI /mL
Study: NCT03978429

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthened Referral Network from Community to Referral hospital levels
Description: ANC nurses and CHWs will play complementary roles in performing activities to meet key indicators and facilitate referrals. They will deliver a plan using the Pre-eclampsia application tool on their smart phone and then they can refer the pregnant woman for enrollment for facility care and track them as per key indicators. The key innovation is that the mHealth platform can detect increases in BP within each patient, and this ability to detect is brought down to the community level through CHWs. This will allow for earlier detection of PE as singular BPs. Nurses will receive protocolized instructions and education regarding when to refer a woman to a higher-level facility for further management. The program consists of SMS component delivered to provide information about participant's condition to relevant members of the referral pathway to enhance referrals and facilitate community level follow up.
Study: NCT03446742

Intervention type: OTHER
Intervention: Cardiovascular rehabilitation
Description: The cardiovascular rehabilitation program is performed three times weekly on alternate days and each session lasts approximately 60 minutes divided as follows: 5 minutes to the initial rest where blood pressure (BP), heart rate (HR) and signs and symptoms are assessed; 15 minutes of warm-up, composed by global stretches, lower and upper limb exercises, and exercises combining the two modes; then, patients go to the resistance phase (30 minutes), where are performed an individualized aerobic protocol according to their HR reserve values using bicycle and treadmill (at the 4th and 10th minute of both ergometers at HR is evaluated, and in the bicycle is also evaluated the BP of all the patients). The end of the protocol is composed of 10-minute relaxation, during which the patients perform a small cardiovascular deceleration (a few laps around the room, with free speed) and, finally, lie down at rest. The presence of signs and symptoms is assessed at all stages of the program.
Study: NCT03826979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pliates method treatment
Description: The participants undergo to a physical therapy rehabilitation program through the Pilates Method for 2 months.
Study: NCT01034488

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Suine
Description: 5000UI/mL
Study: NCT04402476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powder Free Polychloroprene Surgical Gloves, Sterile. Low Dermatitis Potential, tested for use with Chemotherapy drugs.
Description: Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
Study: NCT02838563

Intervention type: OTHER
Intervention: SIWA
Description: To investigate the scale reliability over time, SIWA are assessed twice, ten minutes apart. To investigate the validity of the tool, SIWA is correlated with another quality of life questionnaire (QoL-AD), a quality of health scale including an analog portion (EQ 5D), and a behavioral disorder scale (Neuropsychiatric Inventory, NPI).
Study: NCT04535960

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG + Liraglutide 1.8 MG
Description: Patients will be randomized to initial therapy with empagliflozin 25mg PO daily for 6 weeks. After that, patients in the empagliflozin group will also receive liraglutide 1.8mg SC daily for additional 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG + Liraglutide 1.8 MG
Description: Patients will be randomized to initial therapy with empagliflozin 25mg PO daily for 6 weeks. After that, patients in the empagliflozin group will also receive liraglutide 1.8mg SC daily for additional 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 MG + Empagliflozin 25 MG
Description: Patients will be randomized to initial therapy with liraglutide 1.8 mg SC daily, for 6 weeks. After that, patients will also receive empagliflozin 25mg PO daily for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 MG + Empagliflozin 25 MG
Description: Patients will be randomized to initial therapy with liraglutide 1.8 mg SC daily, for 6 weeks. After that, patients will also receive empagliflozin 25mg PO daily for 6 weeks.
Study: NCT01110707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human follicle stimulating hormone (r-hFSH)
Description: Subjects will receive subcutaneous injection of recombinant human follicular stimulating hormone (r-hFSH) 300-450 International Units (IU) administered after pituitary desensitization according to the ovarian response with gonadotrophin-releasing hormone agonist (GnRH-a; at a dose of 0.1 milligram per day \[mg/day\]).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human luteinizing hormone (r-hLH)
Description: Subjects will receive subcutaneous injection of recombinant human luteinizing hormone (r-hLH) 150 IU/day until the end of ovarian stimulation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human luteinizing hormone (r-hLH)
Description: Subjects will receive subcutaneous injection of recombinant human luteinizing hormone (r-hLH) 150 IU/day until the end of ovarian stimulation.
Study: NCT01998633

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplant
Description: NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~* Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10~* Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4~* Melphalan 140mg/m2 on Day -3~The GVHD prophylaxis will consist of the following:~* Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.~* Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)
Study: NCT03711045

Intervention type: BEHAVIORAL
Intervention: eye-tracking
Description: After completing a demographics form, theBeck Depression Inventory,Beck Anxiety Inventory,Barratt Impulsiveness Scale and Ruminative Response Scale-21, each participant has to go to the eye-tracking room and seats in a height adjustable chair and places their chin in a chin rest which was positioned to make sure all participants' eye are in the same location relative to the camera and the monitor.~There are 18 trials and 2 filler trials in the free-view task, each of which contains 4 pictures on the same screen for 25 seconds. There is also a gap screen between each trial lasting for 2 seconds when participants were asked to fixate in the center of the screen. During the experiment, participants are instructed to watch the screen as naturally as possible, and the initial location of the fixation of each trial and the total dwell time of each emotional images(negative, happy, neutral and suicide-related)and the changes of the pupil size were recorded.

Intervention type: BEHAVIORAL
Intervention: eye-tracking
Description: After completing a demographics form, theBeck Depression Inventory,Beck Anxiety Inventory,Barratt Impulsiveness Scale and Ruminative Response Scale-21, each participant has to go to the eye-tracking room and seats in a height adjustable chair and places their chin in a chin rest which was positioned to make sure all participants' eye are in the same location relative to the camera and the monitor.~There are 18 trials and 2 filler trials in the free-view task, each of which contains 4 pictures on the same screen for 25 seconds. There is also a gap screen between each trial lasting for 2 seconds when participants were asked to fixate in the center of the screen. During the experiment, participants are instructed to watch the screen as naturally as possible, and the initial location of the fixation of each trial and the total dwell time of each emotional images(negative, happy, neutral and suicide-related)and the changes of the pupil size were recorded.

Intervention type: BEHAVIORAL
Intervention: eye-tracking
Description: After completing a demographics form, theBeck Depression Inventory,Beck Anxiety Inventory,Barratt Impulsiveness Scale and Ruminative Response Scale-21, each participant has to go to the eye-tracking room and seats in a height adjustable chair and places their chin in a chin rest which was positioned to make sure all participants' eye are in the same location relative to the camera and the monitor.~There are 18 trials and 2 filler trials in the free-view task, each of which contains 4 pictures on the same screen for 25 seconds. There is also a gap screen between each trial lasting for 2 seconds when participants were asked to fixate in the center of the screen. During the experiment, participants are instructed to watch the screen as naturally as possible, and the initial location of the fixation of each trial and the total dwell time of each emotional images(negative, happy, neutral and suicide-related)and the changes of the pupil size were recorded.
Study: NCT03914040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPSE program
Description: 1. Pre-immersion preparation. A self-study course will be offered about lifestyle modification. Some readings will be suggested to introduce students to the concepts of health promotion and prevention of metabolic syndrome.~2. Immersion. Four different learning methods will be provided: I) four hours of didactic lectures followed by group discussion, II) four hours per student of role playing, III) 30' per students of standardized patient experiences and IV) 30' per students of a new immersive advanced simulation learning environment (e-REAL). Four case-studies will be used to create scenarious, including woman with menopause weight gain, obese young adult, obese child and adult with unhealthy behaviours.
Study: NCT02764151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06840003
Description: Daily Oral PF-06840003
Study: NCT00791544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE1642
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE1642
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE1642
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE1642
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE1642
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE1642
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE1642
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVE1642
Description: intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: oral intake
Study: NCT00456131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating Behaviors Training
Description: The intervention group (other group is a control without any intervention) involves 6 one-hour group sessions teaching healthy eating habits and weight gain prevention tools.
Study: NCT00380250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03022344

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Cardiac CT

Intervention type: RADIATION
Group type: SHAM_COMPARATOR
Intervention: Cardiac CT
Study: NCT02657382

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) Biofeedback (BF)
Description: Heart Rate Variability (HRV) biofeedback involves deep breathing, mindfulness (focusing on one's emotions and thoughts) and cognitive therapy (identifying and changing unhelpful or inaccurate thinking and distressing emotional responses). It is a 6-week training with one hour sessions with a certified biofeedback coach once per week. A handheld personal stress reliever device will be provided to the patients to practice at home for 20 minutes a day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability (HRV) Biofeedback (BF)
Description: Heart Rate Variability (HRV) biofeedback involves deep breathing, mindfulness (focusing on one's emotions and thoughts) and cognitive therapy (identifying and changing unhelpful or inaccurate thinking and distressing emotional responses). It is a 6-week training with one hour sessions with a certified biofeedback coach once per week. A handheld personal stress reliever device will be provided to the patients to practice at home for 20 minutes a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Stress Protocol
Description: Mental stress will consist of a 3-min math serial subtraction paradigm.The participants will be asked to serially subtract 7 from number specified by the researcher. For participants who have difficulty with this task, easier serial subtraction will be provided for. Throughout the task, to increase stressfulness and titrate difficulty, the participant will be prompted for faster performance and the starting number from which they were subtracting will be periodically changed. Finally, to add an evaluation component, participants will be given negative feedback during the test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Stress Protocol
Description: Mental stress will consist of a 3-min math serial subtraction paradigm.The participants will be asked to serially subtract 7 from number specified by the researcher. For participants who have difficulty with this task, easier serial subtraction will be provided for. Throughout the task, to increase stressfulness and titrate difficulty, the participant will be prompted for faster performance and the starting number from which they were subtracting will be periodically changed. Finally, to add an evaluation component, participants will be given negative feedback during the test.
Study: NCT03305198

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Capillary blood sampling from the earlobe
Description: Sample at rest before the walking test Sample at rest 3 minutes after the end of the walking period
Study: NCT03120819

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oncologist Recommendation
Description: Patients in this arm receive a 2-3 minute verbal recommendation about exercise from their treating oncologist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oncologist Recommendation + DVD
Description: Patients in this arm receive a 2-3 minute verbal recommendation about exercise from their treating oncologist and then be sent an instructional exercise DVD to follow at their home three times per week for eight weeks
Study: NCT04459572

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: suPAR
Description: Soluble Urokinase Plasminogen Activator Receptor (suPAR)